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Rapamycin (RAPA) inhibits the mechanistic target of rapamycin (mTOR), a crucial immune system regulator.
Dendritic cells (DC) generated in RAPA (RAPA-DC) enrich for CD4þ forkhead box p3 (FoxP3þ) regulatory T cells
and induce T cell apoptosis by an unknown mechanism. RAPA-DC also promote experimental allograft sur-
vival, yet paradoxically secrete increased IL-12, crucial for the generation of IFN-gþ CD4þ T cells. However,
IFN-g is pro-apoptotic and IL-12-driven IFN-g inhibits experimental graft-versus-host disease (GVHD). We
hypothesized that IL-12hi RAPA-DC would facilitate IFN-g-mediated apoptosis of alloreactive T cells and,
unlike control (CTR)-DC, would reduce lethal GVHD. Following LPS stimulation, RAPA-DC exhibited decreased
MHCII and co-stimulatory molecules and contained a signiﬁcant population of CD86lo IL-12hi cells. Consistent
with our hypothesis, both unstimulated and LPS-stimulated RAPA-DC enhanced alloreactive CD4þ T cell
apoptosis in culture. Augmented T cell apoptosis was ablated by IFN-g neutralization or using T cells lacking
the IFN-g receptor, and it was associated with increased expression of Fas and cleaved caspase 8. DC pro-
duction or responses to IFN-g were not important to increased apoptotic functions of RAPA-DC. LPS-stimu-
lated IL-12p40/ RAPA-DC induced lower levels of T cell apoptosis in culture, which was further decreased
with addition of anti-IFN-g. Finally, whereas CTR-DC accelerated mortality from GVHD, LPS-treated RAPA-DC
signiﬁcantly prolonged host survival. In conclusion, increased apoptosis of allogeneic CD4þ T cells induced by
LPS-stimulated IL-12hi RAPA-DC is mediated in vitro through IFN-g and in part by increased IL-12 expression.
Enhanced production of IL-12, the predominant inducer of IFN-g by immune cells, is a probable mechanism
underlying the capacity of LPS-treated RAPA-DC to reduce GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Dendritic cells (DCs) are important bonemarrowederived
professional antigenpresenting cells that induce and regulate
T cell responses [1-4]. This dichotomy reﬂects DC phenotypic
and functional plasticity. Immature DCs (MHCIIloCD86lo)
display inherent tolerogenicity, whereas mature DCs (MHCIIhi
CD86hi), activated by various stimuli (in particular Toll-like re-
ceptor [TLR] or CD40 ligation and pro-inﬂammatory cytokines),
are potent inducers of adaptive immunity. Numerous immu-
nosuppressive and anti-inﬂammatory agents inhibit DC
maturation and promote their tolerogenicity in vitro and
in vivo [3,5].
Rapamycin (RAPA) inhibits the serine/threonine kinase
mechanistic target of rapamycin (mTOR), a crucial immune
response regulator that integrates environmental signals
leading to cell growth and proliferation [6]. DCs generated
in clinically relevant concentrations of RAPA (RAPA-DCs),edgments on page 200
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13.11.007either in vivo or in vitro, are immature and fail to mature
phenotypically (fully up-regulate MHCII and CD86) [7-12].
They induce apoptosis of polyclonal allogeneic T cells
(referred to hereafter as alloreactive T cells) and enrich for
CD4þFoxP3þ T cells [9,12]. Alloantigen-presenting autolo-
gous RAPA-DCs promote experimental organ allograft
survival, inhibit graft-versus-host disease (GVHD), and
reduce dependence on post-transplant immunosuppres-
sion [9,13].
Paradoxically, mTOR inhibitors cause a dysregulation of
cytokine production by DCs upon their exposure to pro-
inﬂammatory stimuli [11,14,15]. Of particular signiﬁcance,
costimulatory moleculeelow (CD86lo), lipopolysaccharide
(LPS)-stimulated RAPA-DCs secrete increased IL-12 [11,16], a
classical immunostimulatory cytokine that drives T helper
type 1 cell responses. However, both IL-12p40 and the IL-12
receptor (R) have been shown to be integral to the de novo
induction of regulatory Tcells (Treg) [11,17]. In addition, IFN-g
is required for activation-induced T cell death via caspase 8
[18], Fas-dependent apoptosis of donor CD4þ T cells in
experimental GVHD [19], and the induction and function of
Treg [20,21]. Signiﬁcantly, administration of IL-12 inhibits
experimental GVHD, dependent on IFN-gemediated donorTransplantation.
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graft-versus-leukemia (GVL) effects [22-24]. Based on
promising anti-tumor effects in experimental animalmodels,
phase I and II trials of systemic IL-12 were undertaken in
renal cell carcinoma, but excessive morbidity and mortality
halted further investigation [25]. Thus, harnessing the ther-
apeutic capacity of IL-12 for the prevention of GVHD [22-24]
will require novel treatments without systemic, potentially
toxic side effects.
Given our previous demonstration of an increased ca-
pacity of RAPA-DCs to support alloreactive T cell apoptosis
[9,12], we aimed to determine if augmented IL-12 production
by costimulatory molecule poor RAPA-DCs would mediate
apoptosis of CD4þ Tcells through IFN-g. Further, based on the
reported inhibitory effects of both RAPA-DCs [13] and IL-12 in
experimental GVHD [22-24], we completed limited in-
vestigations into the therapeutic capacity of IL-12hi RAPA-DCs
in an experimental model of GVHD, where we hypothesized
they would have augmented capacity to reduce lethal GVHD.
METHODS
Animals
Wild-typeC57BL/6J (B6;H2Kb) andBALB/c (H2Kd), B6.129S7-Ifngr1tm1Agt/
J (IFN-g-R/; H2Kb), CByJ.129S7(B6)-Ifngr1tm1Agt/J (IFN-g-R/; H2Kd), and
B6.129S1-Il12btm1Jm/J (IL-12p40/; H2Kb) mice (Jackson Laboratory; Bar
Harbor, ME, US), 8 to 12 weeks of age, were used, with male mice used for
invitroexperiments and femalemiceused forGVHDexperiments.All animals
were housed in speciﬁc pathogen-free conditions at the University of Pitts-
burgh School of Medicine. Experiments were conducted in accordance with
National Institutes of Health guidelines and under an Institutional Animal
Care and Use Committee approved protocol.
DC Generation and Treatment
Conventional myeloid DCs were generated from B6, IFN-g-R/ (B6),
IL-12p40/ (B6), or BALB/c bone marrow in 7-day culture in murine re-
combinant granulocyte-macrophage colony-stimulating factor and recom-
binant IL-4 (R&D Systems, Minneapolis, MN) in the presence or absence of
RAPA (beginning on day 2 of culture at 10 ng/mL; LC Laboratories, Woburn,
ME) as described [9,26]. DCs remained unstimulated or were treated with
bacterial LPS (TLR-grade LPS from Salmonella minnesota R595; Enzo Life
Sciences, Farmingdale, NY) on day 7 (100 ng/mL) for an additional 18 hours.
On day 8, nonadherent cells were harvested, and CD11cþ DCs were isolated
using anti-CD11c immunomagnetic beads (Miltenyi Biotec; Auburn, CA, US)
for positive selection (purity > 90%).
Mixed Leukocyte Reactions
BALB/c, B6, or IFN-g-R/ (BALB/c) bulk CD4þ T cells were isolated from
spleens as described [10]. Brieﬂy, splenic T cells were puriﬁed by negative
selection of non-T cells using anti-CD11b, -TER-119, -Gr-1, -I-A/I-E, -B220,
and -Gr-1 mAbs (BD PharMingen; San Jose, CA, US) and were removed via
Mouse Depletion Dynabeads (Dynal Biotech, Grand Island, NY). B6, IFN-g-
R/ (B6), or IL-12p40/ (B6) CD11cþ DCs were used as stimulators of pu-
riﬁed allogeneic CD4þ T cells in 5-day (unless otherwise indicated) mixed
leukocyte reactions (MLRs) at a 1:10 ratio in 96-well, round-bottom plates,
with or without anti-IFN-g mAb added on day 1 (1.0 mg/mL, XMG1.2;
eBiosciences; San Diego, CA, US).
Flow Cytometry
DC were analyzed for intracellular expression of IL-12 and for cell surface
expression of CD11c, IAd, CD86, CD80, CD11b, CD8a, CD4, and B220 using
ﬂuorophore-conjugated mAbs (BD Biosciences or eBioscience). T cell
apoptosis was quantiﬁed using an Annexin V-PE Apoptosis Detection kit (BD
PharMingen). T cells were also examined for cell surface CD4 and Fas (CD95)
and for intracellular IFN-g expression using ﬂuorophore-conjugated mAbs
(BD Biosciences or eBioscience). Intracellular expression of cleaved caspase 8
was assessed using primary rabbit mAb (Cell Signaling, Danvers, ME; 8592S)
followed by ﬂuorophore-conjugated anti-rabbit mAb (A31573; Invitrogen,
Grand Island, NY). Isotype-matched IgGs were used as controls. An LSR II or
LSR Fortessa (BD Biosciences, San Jose, CA) was used for data acquisition and
data analyzed using FlowJo (TreeStar, version 8.8.7, Ashland, OR).
Allogeneic Bone Marrow Transplantation and Induction of Lethal GVHD
The capacity of syngeneic DCs to limit GVHD was assessed in lethally
irradiated (800 cGy) female BALB/c recipients reconstituted with 5  106Tcell-depleted B6 bone marrow cells on day 0. CD90.2 microbeads (Miltenyi
Biotec) were used for T cell depletion according to the manufacturer’s rec-
ommendations. Recipient mice were given 1  106 CD11cþ BALB/c DC
(control [CTR], RAPA, or RAPA-DCs exposed to LPS) and 1106 B6 pan T cells
on day 1. Pan T cells were isolated from spleens by negative selection using
the Pan T Isolation Kit (Miltenyi Biotec) according to the manufacturer’s
instructions. Mice in each group were allocated randomly to different cages
to minimize cage-related effects. They received antibiotic water (trimeth-
oprim-sulfamethoxazole; Hi-Tech Pharmacal, Amityville, NY) from day e7
through day þ14.
Clinical GVHD Evaluation
Mice were assessed for GVHD morbidity using a standard scoring
system [27] based on weight loss, posture, activity level, fur texture, and
integrity of skin. The animals were monitored every other day (or more
frequently if indicated), and mice with >20% body weight loss were killed.
Statistical Analyses
Results from pooled completed experiments are expressed as means
(standard deviation [SD] or standard error). The signiﬁcances of differ-
ences between means were determined using Student’s t-test with P < .05
considered as signiﬁcant. Survival curves were generated using GraphPad
Prism 2.0C Software package (GraphPad Software, Inc., La Jolla, CA) with
differences in survival determined by Kaplan-Meier analysis and the log-
rank test.
RESULTS
Costimulatory Molecule-Low, LPS-Stimulated RAPA-DCs
Express High Levels of IL-12 and Induce Apoptosis of
Alloreactive CD4þ T Cells via an IFN-g-Dependent
Mechanism In Vitro
By conventional phenotyping, CD11cþ RAPA-DCs were
very similar to CTR-DCs and displayed a phenotype consistent
with conventional myeloid derived DCs (Supplemental
Figure 1). Compatible with our previous data [11], RAPA-DCs
displayed signiﬁcantly reduced costimulatory molecule
(CD86) expression (representative and aggregate data;
Figure 1A,B) compared with CTR-DCs. RAPA-DCs also signiﬁ-
cantly down-regulated IAd and CD80 (Supplemental Figure 2).
After LPS stimulation, CTR-DCs expressing IL-12p40 displayed
high levels of CD86, where RAPA-DCs retained lower levels of
CD86 but still up-regulated IL-12p40 expression (Figure 1A,B).
Thus, RAPA-DCs after exposure to LPS displayed a dominant
population of CD86loIL-12hi cells (Figure 1A,B). We demon-
strated previously a direct correlation between intracellular
IL-12 expression and secretion of IL-12 by mTOR-inhibited
DCs [11,16]. RAPA-DCs from IL-12p40/ mice also displayed
reduced CD86 levels compared with CTR IL-12p40/ DCs,
both before and after LPS exposure. This suggests that an
IL-12-independent regulatory mechanism suppresses CD86
expression on RAPA-DCs.
We demonstrated previously [9] that unstimulated
or CD40-ligated RAPA-DCs induce increased apoptosis
(Annexin Vþ7-AADþ) of wild-type alloreactive CD4þ T cells
in 5-day MLRs compared with CTR-DC counterparts. Our
present data (Figure 1C,D) conﬁrm the increased capacity
of unstimulated RAPA-DCs to induce apoptosis when used
as stimulators (12.7%  2.3% versus 7.3%  .4%; P < .05).
Importantly, we also now show that LPS-stimulated IL-12hi
RAPA-DCs induce signiﬁcantly more apoptosis compared
with CTR-DCs (RAPA þ LPS: 28.5%  4.4% versus 15.4% 
2.9%; P < .05) (Figure 1C, representative data; Figure 1D,
average across 3 experiments normalized to CTR). IL-12p70
is the principal inducer of IFN-g production by immune
cells, especially CD4þ T cells [28]. However, even while
supporting T helper type 1 responses, IFN-g is necessary for
activation-induced cell death of T-cell receptor-stimulated
T cells [18]. LPS-stimulated RAPA-DCs induced augmented
apoptosis of allogeneic CD4þ T cells (Figure 1). Given that
Figure 1. LPS-stimulated RAPA-DCs express high IL-12 despite low costimulatory molecule expression and induce apoptosis of alloreactive CD4þ T cells in an IFN-g-
dependent manner. C57BL/6 (B6; H-2b) and IL-12p40/ (B6) myeloid DCs (mDC) were generated in 7-day culture with granulocyte-macrophage colony-stimulating
factor and IL-4 alone (CTR-DC) or in the presence of 10 ng/mL RAPA (RAPA-DC). CD11c-puriﬁed mDCs were incubated for 18 hours in media alone or with 100 ng/mL
LPS and then analyzed for cell surface molecule expression by ﬂow cytometry. B6 mDCs were then used in 5-day MLRs to stimulate BALB/c (H2d) CD4þ T cells. (A)
RAPA-DCs, especially after LPS exposure, express low levels of CD86 and high levels of IL-12 compared with LPS-exposed CTR-DCs (CD86loIL-12hi population). IL-
12p40/ LPS-stimulated RAPA-DCs lack a high IL-12 population but have a similar CD86lo population compared with wild-type. (B) The percentage of CD86hi IL-12lo,
CD86hi IL-12hi, and CD86lo IL-12hi from 7 independent experiments was averaged. Data depict mean þ 1 SD. (C) Compared with CTR-DCs, especially after LPS
stimulation, RAPA-DCs induced increased apoptosis (Annexin Vþ7-AADþ) of alloreactive CD4þ T cells (12.7%  2.3% versus 7.3%  .4%; þLPS: 28.5%  4.4% versus 15.4%
 2.9%; both P < .05). Blocking the activity of IFN-g in LPS-treated RAPA-DC cultures decreased levels of apoptosis to those of LPS-treated CTR-DCs (18.7%  1.0%
versus 15.4%  2.9%; NS). Plots are representative of 3 experiments performed. (D) Average fold increase in CD4þ Annexin Vþ 7-AADþ relative to CTR-DCs on day 5 of
MLRs. Error bars indicate mean þ 1 SD. n ¼ 3. *P < .05.
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production by CD4þ T cells [29], we investigated the role of
IFN-g in the pro-apoptotic function of RAPA-DCs using
neutralizing Abs. The apoptosis of alloreactive CD4þ T cell
induced by LPS-stimulated IL-12hi RAPA-DCs was decreased
signiﬁcantly when IFN-g was blocked via anti-IFN-g mAb
(Figure 1C,D). In fact, with anti-IFN-g mAb added to LPS-
stimulated RAPA-DC cultures, the degree of apoptosis was
reduced to levels similar to those induced by LPS-
stimulated CTR-DCs (18.7%  1.0% versus 15.4%  2.9%;
NS). Thus, apoptosis of alloreactive CD4þ T cells promoted
by RAPA-DC in vitro is mediated, at least in part, by IFN-g, a
cytokine driven by IL-12 that is expressed at high levels by
LPS-stimulated RAPA-DCs.
IL-12hi RAPA-DCs Induce Increased Production of IFN-g
by CD4þ T Cells
Given that apoptosis of CD4þ T cells driven by IL-12hi
RAPA-DC is dependent on IFN-g, we next sought to deter-
mine which cells were producing IFN-g. IFN-g expression
was not detected in the supernatants of any DC groups by
ELISA (CTR  LPS or RAPA  LPS; data not shown). As re-
ported previously [11], production of IFN-g by CD4þ T cellswas not altered when assessed on day 5 of MLR with LPS-
stimulated RAPA-DCs. Therefore, we analyzed IFN-g pro-
duction at earlier time points during MLRs (day 1 and day 2).
As shown in Figure 2, both unstimulated RAPA-DCs and LPS-
stimulated RAPA-DCs induced increased IFN-g production by
CD4þ T cells compared with CTR groups (day 1: 3.2  .8
versus 10.6  .9; LPS: 6.1 1.2 versus 10.6  2.1; P < .05; day
2: 3.6 2.1 versus 10.5 5.9; LPS: 6.0 3.1 versus 10.13.4;
P < .05) (Figure 2A representative data, Figure 2B average
across 3 experiments normalized to CTR). Therefore, IL-12hi
RAPA-DC promote apoptosis of alloreactive CD4þ T cells via
induction of IFN-g by the T cells, not the DCs.
Apoptosis of Alloreactive CD4þ T Cells Induced by LPS-
Exposed IL-12hi RAPA-DCs Depends on T Cell But Not DC
Responses to IFN-g
Using a neutralizing Ab, we determined that IFN-gwas an
importantmediator of the increased apoptosis of alloreactive
CD4þ T cells induced by LPS-stimulated RAPA-DCs. We next
performed studies to determine whether IFN-gwas acting in
this capacity on DCs, CD4þ T cells, or both. When exposed to
LPS-stimulated IL-12hi RAPA-DCs, IFN-g-R/ CD4þ T cells
exhibited decreased apoptosis (Annexin Vþ7-AADþ) in 5-day
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1.9% versus IFN-g-R/ 6.4%  3.1%; þLPS: 15.6%  3.6%
versus 4.9%  1.1%; P < .05 for LPS) (Figure 3A representative
data; Figure 3B average across 2 experiments normalized to
CTR). Unlike those of CD4þ T cells, DC responses to IFN-g
were not important in mediating the function of RAPA-DCs
(Figure 3C representative data; Figure 3D average across 2
experiments normalized to CTR). There was no difference in
the extent of apoptosis of alloreactive CD4þ T cells induced
by IFN-g-R/ RAPA-DCs compared with wild-type RAPA-
DCs (12.4%  7.6% versus 10.5%  7.6% respectively; þLPS:
27.2%  11.9% versus 30.1%  16.3%; both NS; Figure 3). The
addition of anti-IFN-g mAb to LPS-stimulated IFN-g-R/
RAPA-DCs signiﬁcantly decreased levels of CD4þ T cell
apoptosis similar to LPS-stimulated wild-type CTR-DCs
(18.0%  10.3% versus 21.9%  6.3%; P ¼ NS; Figure 3D).
These data strongly support the conclusion that IFN-g me-
diates increased apoptosis of alloreactive T cells directly and
not through actions on DCs.Induction of Apoptosis by LPS-Stimulated RAPA-DCs
Depends on IL-12 Expression
Using IL-12p40/ DCs, we next explored the role of DC
IL-12 expression in the increased apoptosis of CD4þ T cells
induced by RAPA-DC. As shown in Figure 4, LPS-stimulated
IL-12p40/ RAPA-DCs induced lower levels of apoptosis in
5-day MLRs, deﬁned by Annexin Vþ 7-AADþ T cells,
compared with wild-type DC (16.9%  8.9% versus 20.8% Figure 2. IL-12hi RAPA-DCs induce increased production of IFN-g by CD4þ T cells. B6 m
or 2-day MLRs to stimulate BALB/c CD4þ T cells. Plots are representative of 3 indepen
LPS-stimulated RAPA-DCs produce increased IFN-g compared with CTR groups (day 1:
2.1 versus 10.5  5.9; LPS: 6.0  3.1 versus 10.1  3.4, P < .05). (B) Average fold increas
mean þ 1 SD. n ¼ 3. *P < .05.10.0%; P < .05) (Figure 4A representative data; Figure 4B
average across 3 experiments normalized to CTR LPS). The
addition of anti-IFN-g to MLRs further decreased apoptosis
of alloreactive CD4þ T cells induced by LPS-stimulated
IL-12p40/ RAPA-DCs (12.0%  6.1% versus 16.9%  8.9%;
P < .05).CD4þ T Cells Interacting with IL-12hi RAPA-DCs Exhibit
Increased Fas and Cleaved Caspase 8
Based on the importance of the Fas pathway in IFN-g-
dependent activation-induced cell death and apoptosis
of donor CD4þ T cells in experimental GVHD [18,19], we
assessed if either the Fas receptor or the downstream pro-
apoptotic effector caspase 8 is modulated on CD4þ T cells
after 1 and 2 days co-culture with RAPA-DCs. Both unsti-
mulated and LPS-stimulated RAPA-DCs enhanced the
expression of Fas on CD4þ T cells compared with their
respective CTR-DC counterparts, particularly after a 1-day
exposure (day 1: 3.3  .8 versus 1.3  .6, LPS: 7.1  1.4
versus 3.5  1.0, P < .05; day 2: 4.1 1.5 versus 1.9  1.5, P <
.05; LPS: 6.6  2.4 versus 3.1  1.6, P ¼ .05) (Figure 5A
representative data; Figure 5B average across 3 experiments
normalized to CTR). Compared with CTR-DCs, RAPA-DCs
stimulated increased expression of cleaved caspase 8 in CD4þ
T cells, particularly after a 2-day co-culture (day 1: 14.2  5.3
versus 9.2 4.7, P< .05; LPS: 14.2 2.4 versus 10.6 4.0, P>
.05; day 2: 11.4  5.6 versus 6.2  3.9, P < .05; LPS: 10.9 6.6
versus 8.7  4.2, P > .05) (Figure 5C representative data;yeloid DCs (mDC) were generated as described in Figure 1 and then used in 1-
dent experiments performed. (A) CD4þ T cells exposed to either RAPA-DCs or
3.19  .8 versus 10.6  .9; LPS: 6.1 1.2 versus 10.6  2.1, P < .05; day 2: 3.62 
e in CD4þ IFN-gþ relative to CTR-DCs on days 1 or 2 of MLRs. Error bars indicate
Figure 3. Apoptosis induced by IL-12hi RAPA-DCs is dependent on T cell but not DC responses to IFN-g. Wild type B6 or B6 IFN-g-R/ DC were generated then used in
5-day MLRs to stimulate wild-type BALB/c or IFN-g-R/ (H2d) CD4þ T cells. Plots are representative of 3 independent experiments performed. (A) IFN-g-R/ CD4þ T
cells have decreased levels of apoptosis (Annexin Vþ7-AADþ) compared with wild-type T cells after exposure to LPS-treated IL-12hi RAPA-DCs (wild-type 5.5%  1.9%
versus IFN-g-R/ 6.4%  3.1%; þLPS: 15.6%  3.6% versus 4.9%  1.1%; P < .05 for LPS). (B) Average fold increase in CD4þ Annexin Vþ 7-AADþ cells relative to CTR-DCs
on day 5 of MLRs. Error bars indicate mean þ 1 SD. n ¼ 2. *P < .05. (C) IFN-g-R/ IL-12hi RAPA-DCs induce similar apoptosis (Annexin Vþ7-AADþ) of CD4þ T cells
compared with wild-type (12.4%  7.6% versus 10.5%  7.6%, respectively; þLPS: 27.2%  11.9% versus 30.1%  16.3%; both NS). However, blocking IFN-g signiﬁcantly
decreased apoptosis induced by LPS-stimulated IFN-g-R/ RAPA-DCs to levels similar to LPS-stimulated wild-type CTR-DC (18.0%  10.3% versus 21.9%  6.3%, P ¼
NS). (D) Average fold increase in CD4þ Annexin Vþ 7-AADþ cells relative to wild-type CTR-DCs on day 5 of MLRs. Error bars indicate mean þ 1 SD. n ¼ 2. *P < .05.
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n ¼ 3 for day 1 and n ¼ 4 for day 2). These data suggest that
FaseFasL interaction and cleavage of caspase 8 may be
important mechanisms downstream of IFN-g that promote
apoptosis of CD4þ T cells by IL-12hi RAPA-DC.
IL-12hi RAPA-DCs Limit GVHD Lethality
Both RAPA-DCs [13] and IL-12 have been reported to
inhibit experimental GVHD [22-24]; thus, we next investi-
gated the therapeutic capacity of IL-12hi RAPA-DCs in an
experimental model of GVHD. Previous work by Reichardt
et al. [13] found that syngeneic DCs exposed to RAPA for 24
hours inhibited GVHD in a B6/BALB/c model of bone
marrow transplantation. We sought to expand on this work
using LPS-stimulated RAPA-DCs, which we hypothesized
would have augmented ability to inhibit GVHD potentially
through their increased IL-12 expression.
CTR- or RAPA-DCs were generated as described in
Methods and either left unstimulated or stimulated with LPS
to induce IL-12 expression. Given a known mTOR poly-
morphism in BALB/c compared with B6 mice [30], we veri-
ﬁed that exposure to RAPA and LPS down-regulated CD86
and up-regulated IL-12 expression by BALB/c DCs similarly to
B6 DCs [11,16]. Using ﬂow cytometry, DCs were analyzed for
cell surface costimulatory molecule expression (Figure 6A).
As expected, RAPA-DCs, compared with CTR-DCs, exhibited
decreased expression of MHC II (IAd), CD80, and CD86
compared with CTR-DC, both with and without LPSstimulation. As shown in Figure 6B, LPS-stimulated BALB/c
RAPA-DCs also had profoundly up-regulated IL-12 compared
with LPS-stimulated CTR-DCs. These ﬁndings conﬁrmed that
BALB/c DC exposed to RAPA and LPS down-regulate CD86
and up-regulate IL-12 similarly to B6 DCs, despite a poly-
morphism in mTOR of BALB/c mice that potentially could
alter effects of RAPA [30].
Autologous BALB/c DCs (CTR-DCs  LPS or RAPA-DCs 
LPS) were administered as negative cellular vaccines
at the time of bone marrow transplantation, in a fully
MHC-mismatched model of acute lethal GVHD
(B6/BALB/c). Host IL-12hi RAPA-DC signiﬁcantly pro-
longed host survival (median survival in days: GVHD, 17.5
days; RAPA-DCs, 25 days, P ¼ NS; IL-12hi RAPA-DCs, 38
days, P ¼ .007; syngeneic control, >50 days, P ¼ .002)
(Figure 6C). In contrast, mice given CTR-DCs  LPS had
similar GVHD mortality to untreated control mice (CTR-
DCs: 8 days; LPSeCTR-DCs: 11 days, both P ¼ NS). These
data demonstrate that syngeneic LPS-stimulated RAPA-
DCs can prolong survival from GVHD when given as a
negative cellular vaccine.
DISCUSSION
DCs are of critical importance in determining the balance
between immunity and tolerance [31], and numerous studies
have demonstrated the in vitro generation of tolerogenic
(tol)DCs with potent modulating effects on autoimmunity
[32] and allograft rejection [3,4,33,34]. TolDCs resemble
Figure 4. Apoptosis of alloreactive CD4þ T cells induced by IL-12hi RAPA-DCs is dependent on IL-12 expression. Wild-type B6 or B6 IL-12p40/ myeloid DCs (mDC)
were generated and then used in 5-day MLRs to stimulate BALB/c CD4þ T cells. Plots are representative of 3 independent experiments performed. (A) LPS-exposed IL-
12p40/ RAPA-DCs induce decreased apoptosis (Annexin Vþ7-AADþ) of alloreactive CD4þ T cells compared with wild-type (16.9%  8.9% versus 20.8%  10.0%; P <
.05). Blocking IFN-g further decreased apoptosis stimulated by LPS-exposed IL-12p40/ RAPA-DCs (12.0%  6.1% versus 16.9%  8.9%, P < .05). (B) Average fold
increase in CD4þ Annexin Vþ 7-AADþ cells relative to wild-type CTR-DCs on day 5 of MLRs. Error bars indicate mean þ 1 SD. n ¼ 3. *P < .05.
E.O. Stenger et al. / Biol Blood Marrow Transplant 20 (2014) 192e201 197quiescent or “immature” DCs in vivo, which under steady-
state, noninﬂammatory conditions express low levels of
surface MHC and costimulatory molecules (eg, CD40, CD80,
CD86) [1,3]. Both tolDCs and immature DCs can induce un-
responsiveness, or anergy, and apoptosis in naïve T cells,
support Treg, and inactivate/delete memory and effector
CD8þ T cells [3,4]. However, DC immaturity is not ﬁxed, and
the sensing of danger signals by DCs triggers signaling
pathways that direct DC “maturation” [1]. Mature DCs have
increased T cell-stimulatory capacity through augmented
surface expression of MHC and costimulatory molecules,
particularly CD86. Likewise, different stimuli trigger re-
ceptors on DCs to launch the appropriate production of cy-
tokines needed to facilitate differentiation of naïve CD4þ T
cells [35]. These receptors, including the well-described TLR
family, detect local “danger,” including exogenous pathogens
via recognition of pathogen-associated molecular patterns
and tissue damage sensed via damage-associated molecular
patterns. Damage-associatedmolecular pattern or pathogen-
associated molecular pattern triggering of most TLRs, espe-
cially TLR4, results in DC secretion of IL-12p70, a cytokineneeded for naïve CD4þ T cell differentiation to IFN-g-
secreting T helper type 1 cells [36].
Many signaling pathways activated by danger signals are
integrated bymTOR,which functions in at least 2 intracellular
complexes to correlate appropriate cell growth/proliferation
and movement with signals arising from environmental
stimuli (ie, growth factors, cytokines, TLR ligands, etc.) and
internal cellular conditions (ie, levels of adenosine triphos-
phate, arachidonic acid, or oxygen) [6]. RAPApotently inhibits
mTOR, and DCs exposed to RAPA have shown promise as
tolDC, speciﬁcally promoting experimental organ allograft
survival, inhibiting GVHD, and reducing the need for con-
tinued post-transplant immunosuppression [9,13]. Both
in vitro and in vivo, exposure to RAPA suppresses DC gener-
ation, phenotypic maturation, and T cell stimulatory function
[6,9-11,26]. Also consistent with tolerogenic functions, RAPA-
DCs induce alloreactive Tcell anergy [26] and apoptosis [9,12]
while enriching for Treg in vitro and in vivo [9,11,16]. How-
ever, when exposed to inﬂammatory stimuli, although RAPA-
DCs fail to fully up-regulate costimulatory molecule (CD86)
expression and remain poorly stimulatory, paradoxically,
Figure 5. Apoptosis of CD4þ T cells by induced IL-12hi RAPA-DCs is dependent on the Fas/FasL pathway and caspase 8. B6 were generated and then used in 1- or 2-day
MLRs to stimulate BALB/c CD4þ T cells. Plots are representative of 3 to 4 independent experiments performed (n ¼ 4 for 2-day MLRs for caspase 8). (A) After exposure
to IL-12hi RAPA-DCs, CD4þ T cells increased expression of Fas compared with LPS-stimulated CTR-DCs, particularly after a 1-day exposure (day 1: 7.1 1.4 versus 3.5 
1.0, P < .05; day 2: 6.6  2.4 versus 3.1  1.6, P ¼ .05). (B) Average fold increase in CD4þ Fasþ cells relative to wild-type CTR-DCs on day 1 or 2 of MLRs. Error bars
indicate mean þ 1 SD. n ¼ 3. *P < .05. (C) CD4þ T cells also up-regulate cleaved caspase 8 expression after exposure to IL-12hi RAPA-DC compared with CTR-DCs,
particularly after a 2-day MLR exposure (day 1: 14.2  2.4 versus 9.2  4.7, P ¼ .05; day 2: 10.9  6.6 versus 6.2  3.9, P < .05). (D) Average fold increase in
CD4þ cleaved caspase 8þ cells relative to wild-type CTR-DCs on day 1 or 2 of MLRs. Error bars indicate mean þ 1 SD. n ¼ 3 (1 day) or 4 (2 day). *P < .05.
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enhanced inﬂammatory IL-12 production and reduced IL-10
[11,14,37]. We have shown that this enhanced IL-12p70 pro-
duction results from RAPA blocking mTOR inhibition of
glycogen synthase kinase-B after TLR4 ligation [11].
Current knowledge suggests that IL-12hi DCs would act as
potent generators of IFN-g production by CD4þ cells [38].
Likewise, RAPA-enhanced IL-12 expression by DCs has been
hypothesized to underlie recent reports of mTOR inhibition
facilitating T cell responses to pathogens [39,40] and the
occurrence, in a subset of RAPA-treated transplant patients,
of inﬂammatory disorders, including interstitial pneumonitis
[41] and glomerulonephritis [42]. However, post-transplant
RAPA fails to enhance donor-speciﬁc T cell responses, even
during concurrent infection [43]. Clinically, mTOR inhibition
is typically associated with increased or maintained levels of
in Foxp3þ T cells, unlike calcineurin inhibitors, which de-
crease Foxp3þ T cell incidence [44,45]. Likewise, as shown in
Figure 1A, augmented IL-12p40 expression by LPS-exposed
RAPA-DCs is dominated by a poorly stimulatory, cos-
timulatory moleculeelow (CD86lo) subset [11]. Importantly,
we now establish that increased IL-12 production by RAPA-
DCs supports IFN-g-mediated apoptosis in vitro (Figure 4),andwehave observed previously that IL-12p70 supports Treg
induction [11].
In the present study, although IFN-g was crucial to the
increased apoptosis induced by RAPA-DCs relative to CTR-
DCs after their exposure to LPS, we did not observe that
blocking IFN-g signiﬁcantly modulated the incidence of Treg
(data not shown). Given the growing use of mTOR inhibitors
in both transplantation and other medical areas, it will be
important to continue to establish how RAPA-mediated
modulation of cytokines, such as IL-12 and IL-10, impact
alloimmunity and transplant survival in relevant experi-
mental models.
Our current ﬁndings also provide new insight into the
mechanisms by which RAPA-DCs promote apoptosis of
alloreactive CD4þ T cells [9]. Speciﬁcally, we reveal that
RAPA-DC-mediated apoptosis of alloreactive CD4þ T cells is
IFN-g-dependent and that the IFN-g-dependent effects are
the result of IFN-g produced by T cells that interact with
RAPA-DCs. Our current studies also demonstrate that this
effect is mediated through IFN-g action on CD4þ T cells and
involves their increased expression of Fas and cleaved cas-
pase 8. However, we ﬁnd that the ability of IFN-g to drive
apoptosis is not due to its capacity to increase DC expression
Figure 6. Autologous IL-12hi RAPA-DC demonstrate low costimulatory molecule expression and inhibit acute GVHD. BALB/c CTR- and RAPA-DCs were generated and
then analyzed for cell surface marker expression using ﬂow cytometry. (A) Compared with equivalent CTR-DC groups, unstimulated RAPA- and LPS-exposed RAPA-
DCs showed decreased surface expression (MFI) of IAd, CD86, and CD80. (B) BALB/c LPS-stimulated RAPA-DCs demonstrate increased IL-12 expression relative to LPS-
stimulated CTR-DCs (CD11cþ IL-12hi population 67.3% versus 16.3%). (C) Lethally irradiated BALB/c recipients were given 5  106 B6 bone marrow cells plus 1  106
puriﬁed B6 T cells alone (GVHD control) or with 1  106 BALB/c DCs (CTR-DC  LPS or RAPA-DC  LPS). Irradiated BALB/c mice injected with syngeneic BALB/c bone
marrow (syngeneic) are also indicated. Although mice receiving CTR-DCs had survival comparable with the control GVHD group (without DCs) (median survival in
days: GVHD, 17.5 days; CTR, 8 days; CTR-LPS, 11 days; all P ¼ NS), IL-12hi RAPA-DCs signiﬁcantly and markedly prolonged survival from GVHD (median survival in
days: 38 days, P ¼ .007).
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causes local tryptophan depletion and release of kynurenines
that cause caspase 8 cleavage and T cell apoptosis [46,47].
Further studies are required to determine whether the CD4þ
T cell apoptosis induced by IL-12hi RAPA-DCs is also depen-
dent on other cytokines dysregulated by mTOR inhibition or
on the low costimulatory molecule expression by these cells.
Based on work by Sykes and colleagues [19,22-24]
demonstrating inhibition of experimental GVHD with IL-12,
we hypothesized that IL-12hi RAPA-DCs could provide a
novel approach to harness the immunoregulatory properties
of IL-12, without themorbidity andmortality associatedwith
its systemic administration in clinical trials [25]. Although IL-
12 has classically been described as an immunostimulatory
cytokine that can mediate or intensify experimental GVHD
[48,49], the timing and dosing of IL-12 is crucial in deter-
mining its effects. Thus, IL-12 inhibits GVHDwhen given early
(1 hour before or 1 to 12 hours after bone marrow trans-
plantation) but enhances GVHD when given late [50]. Our
data suggest that RAPA-DCs are indeed an effective means
to deliver IL-12 early after bone marrow transplantation
and are compatible with the ability of IL-12 delivered with
bone marrow transplantation to inhibit GVHD.
In the current studies, unstimulated RAPA-DCs failed to
signiﬁcantly prevent experimental GVHD. This is distinct
from studies by Reichardt et al. [13], where splenic and bone
marrow CD11cþ cells exposed to RAPA for 24 hours andinfused with T cells after bone marrow transplantation were
effective in prevention of GVHD. However, given the differ-
ences in preparation of RAPA-DCs between these studies and
the lack of assessment by Reichardt et al. as towhether RAPA-
DCs generated in this fashion overexpress IL-12, it is difﬁcult
to establish reasons for the differences in effectiveness be-
tween unstimulated RAPA-DCs in these two studies. Yet in
these independent investigations, unstimulated syngeneic
RAPA-DCs [13] or LPS-stimulated RAPA-DCs (the present
report) delivered at the time of bonemarrow transplantation
have shown therapeutic beneﬁt against GVHD. This is in
contrast to CTR-DCs, which in both studies accelerated
GVHD.
Previous work by Sykes and colleagues [22-24] demon-
strated that GVHD protection through the administration of
systemic IL-12 was IFN-g dependent. In addition, IL-12 pre-
served important experimental GVL effects, also mediated
through IFN-g [23]. However, expansion to the clinical
setting was halted because of excessive morbidity and mor-
tality in phase I and II trials [25]. Both human and mouse DCs
generated in or pulsedwith RAPA express CCR7 at levels at or
above CTR-DCs [9,13,51], and after their infusion, mouse
RAPA-exposed DCs trafﬁc to the secondary lymphoid tissue
[13,26]. Thus, LPS-stimulated RAPA-DCs may enable targeted
delivery of IL-12 to host lymphoid tissues without the toxic
effects of IL-12 therapy as seen in clinical trials. We propose
that increased IL-12 production may underlie the capacity of
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prolonging allograft survival. The present study does not
include robust mechanistic in vivo studies to verify this
hypothesis; therefore, future experiments are warranted to
determine if IL-12p40/ or IL-12p35/ RAPA-DCs exposed
to LPS retain the capacity to promote resistance to GVHD.
These future studies will also provide the opportunity for
precise histopathological assessment of GVHD target organs
to further support the therapeutic beneﬁt of RAPA-DCs
secreting IL-12.
GVHD remains a signiﬁcant cause of post-transplant
morbidity and mortality and limits the broader application
of hematopoietic stem cell transplantation, such as to pa-
tients with nonmalignant diseases or without a matched
related donor. Given the known role of DCs in the patho-
genesis of GVHD [4] and the failure of therapies that target
effector T cells to adequately prevent or treat GVHD, ap-
proaches that target DCs or DC cellular therapies are an
attractive emerging strategy [4]. DCs are also required for full
GVL effects (host > donor DC) [52-54], and, importantly,
modulation of donor DC subsets [55,56] and the adminis-
tration of tolDCs [57] has been shown to preserve these
crucial GVL effects while abrogating experimental GVHD.
Clinical trials using cellular therapies for GVHD, including
Treg and mesenchymal stem cells, are underway [4], and
human tolDCs have been generated and characterized
in vitro using clinical grade reagents and proven safe in initial
phase I clinical testing in newly diagnosed cases of type 1
diabetes and rheumatoid arthritis [58-61]. It can be easily
envisioned that these advances in DC cellular therapy will
lead to future trials of tolDCs in GVHD. Further in vivo
experimental studies of IL-12hi RAPA-DCs are clearly indi-
cated to both elucidate the role of cellular IL-12 in their
prevention of GVHD and directly assess if GVL effects are
preserved or potentiated.ACKNOWLEDGMENTS
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